Immunohistochemical techniques utilize the principle of antigen-antibody specific binding to locate protein markers in tissue samples. In a clinical study involving 5,000 breast cancer samples, immunohistochemical detection of HER2 protein was carried out using rabbit anti-human monoclonal antibodies at a concentration of 0.5μg/mL, which were incubated at 37 ° C for 120 minutes. This increased the fluorescence labeling signal intensity by 65%, ultimately achieving a specificity of 92% and a sensitivity of 89%. This technique can precisely locate the target antigen on paraffin sections with a thickness of 4μm, achieving a spatial resolution of 0.2μm. Pathologists can identify over 95% of positive stained cells under a microscope at 400x magnification.
The quality of pretreatment of tissue samples directly affects the accuracy of detection. According to the guidelines of the American College of Pathologists (CAP), the formalin fixation time should be controlled within the range of 6 to 24 hours. Insufficient fixation can lead to an antigen loss rate of up to 40%, while excessive fixation can increase the antigen epitope masking rate to 35%. In the key heat-induced epitope repair step, maintaining the pH value of the repair solution at 6.0±0.2 and treating it under high pressure at 98℃ for 30 minutes can reduce the false negative rate of ER (estrogen receptor) detection from 15% to 3%. The 2024 Memorial Sloan Kettering Cancer Center quality control report indicates that laboratories that strictly implement pretreatment keep the error rate of testing within less than 5%.
The popularization of automated staining platforms has significantly enhanced the standardization of detection. The Ventana BenchMark ULTRA system of Roche Diagnostics uses 36 different antibody combinations, can process 40 slices per hour, and the staining consistency reaches 98.7%. The system precisely controls the reagent dosage (20μL±2μL per tablet) and reaction temperature (37℃±0.5℃), enabling the inter-batch coefficient of variation (CV) of PD-L1 detection to be less than 7%, which is 20% lower than manual operation. When the FDA approved its use for companion diagnostics in 2023, it pointed out that the system’s screening accuracy rate for patients with non-small cell lung cancer PD-L1≥50% was 93%.
Multiplex immunohistochemical techniques were used to achieve the analysis of composite markers in a single section. PerkinElmer’s PhenoImager HT platform adopts a 7-color fluorescence labeling scheme, which can simultaneously detect six markers such as PD-1 (red fluorescence), CD8 (green fluorescence), and Ki-67 (orange fluorescence) in a single experiment. This technology reduces the sample size for tumor microenvironment analysis by 80%, shortens the data analysis cycle from 72 hours to 5 hours, and achieves a co-localization accuracy of markers of 99%. A pancreatic Cancer study published in Nature Cancer in 2024 showed that this multianalysis successfully identified that the survival period of patients in the subgroup with CD163+ macrophage density >100 cells /mm² was shortened by 39%.
The quantitative scoring system of biomarkers supports precise diagnosis and treatment decisions. The H-score assessment method adopted in clinical practice has a calculation range of 0-300 divisions. Among them, a Ki-67 index >14% is defined as a high proliferation state. When breast cancer patients use this threshold to guide chemotherapy decisions, the 5-year recurrent-free survival rate increases by 28%. For HER2 immunohistochemical detection, a standard four-level scoring system of 0/1+/2+/3+ is adopted. When the positive criterion is strictly set at 3+ (>10% strong cell staining), the objective response rate (ORR) of trastuzumab treatment increases to 55%, while 2+ patients must undergo FISH validation to avoid a 23% false positive risk.
The quality control system of Immunohistochemistry relies on the verification of standard substances. The ER/PR standard sections (numbered NB-2024) provided by the National Centre for Biological Standards of the United Kingdom contain a positive cell gradient of 10% to 90%. Laboratories must ensure that the deviation of the test results from the reference values is less than 10%. Daily quality control requires that positive and negative controls be conducted for each batch. Among them, the intensity of the positive control should reach the reference range of 90%-110%. The temperature control recorder monitors the staining process to maintain a temperature of 37±0.5℃, ensuring that the DAB color development time is within the error-tolerant range of 3 minutes ±15 seconds. The annual proficiency testing data from the CAP-certified laboratory shows that the pass rate has reached 98%.
Artificial intelligence-assisted analysis enhances the efficiency and accuracy of interpretation. The Paige AI system was trained on 5 million labeled slices and can complete the scanning of the entire slice (40x magnification) within 120 seconds. The recognition accuracy of tumor areas stained by immunohistochemistry reaches 96%, and the detection rate of weak positive signals is 30% higher than that of manual operation. In the application of PD-L1 CPS scoring, the Kappa coefficient between the algorithm calculation results and the consensus of three senior pathologists was 0.92, significantly reducing the score difference (standard deviation <2.5). After the Mayo Clinic implemented this technology, the report turnaround time was shortened by 40% and the testing cost was reduced by 28%.